The proportion, clinical predictors, and prognostic impact of hypometabolic estrogen receptor–positive primary breast cancer on baseline [18F] fluorodeoxyglucose PET
A considerable proportion of estrogen receptor-positive breast tumours showed low SUVmax, indicating potential suboptimal staging on [18F]FDG PET. In patients with lower cT-status, lobular histology and low-grade estrogen receptor-positive tumour, [18F]FDG PET may be less reliable as staging procedure. Further research is necessary to determine the optimal metabolic threshold for defining a hypometabolic tumour.
Authors
- Melissa Lenaerts (ORCID: https://orcid.org/0000-0001-9687-4375)
- Tineke van de Weijer (ORCID: https://orcid.org/0000-0003-3485-7881)
- Thiemo J A van Nijnatten
- Vivianne C.G. Tjan-Heijnen
- Felix M. Mottaghy
- Marjolein L. Smidt
- Lois van der Voort
- Sandra M.E. Geurts
- Luigi Aloj
- Adri C. Voogd
- Ferdia A. Gallagher
Institutions
- University of Cambridge (GB)
- University Medical Center (US)
- Maastricht University (NL)
- University Hospital and Clinics (US)
- RWTH Aachen University (DE)
Publication Details
- Journal
- Nuclear Medicine Communications
- Published
- 2026-02-25
- DOI
- https://doi.org/10.1097/mnm.0000000000002133
- Primary Topic
- Medical Imaging Techniques and Applications
- Type
- article
- Field-Weighted Citation Impact
- 0.00